CanCuRX is a preclinical-stage biopharmaceutical company aiming to improve survival for patients with pancreatic cancer through the development of a novel treatment based on the properties of a mushroom-derived compound that arrests pancreatic cell growth. CanCuRX is working with the Carmel Innovations Fund of the University of Haifa. CanCuRX has patents registered for the mushroom strain, the extract prepared from it, and the treatment process.